Yoon Hang Kim, MD, MPH

Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

www.directintegrativecare.com

Introduction: The Brain’s Metabolic Vulnerability

The human brain, despite comprising roughly two percent of total body mass, consumes approximately twenty percent of the body’s resting energy expenditure and oxidizes on the order of 120 to 130 grams of glucose per day under normal circumstances. This extraordinary metabolic demand makes the brain uniquely vulnerable to disruptions in energy supply. In neurodegenerative disease, traumatic brain injury, epilepsy, and even the slow metabolic erosion of aging, one of the earliest and most consistently documented abnormalities is a decline in cerebral glucose uptake and utilization. Positron emission tomography studies have demonstrated regional cerebral glucose hypometabolism years before the onset of clinical symptoms in conditions such as Alzheimer’s disease, suggesting that energetic failure may be among the earliest pathological events rather than a late consequence of neuronal loss.

Against this backdrop, nutritional and exogenous ketosis has attracted growing scientific attention not merely as a weight-management strategy, but as a fundamentally different metabolic state that may shift brain energy supply, modulate inflammation, alter epigenetic signaling, and enhance neuronal resilience. The ketone bodies β-hydroxybutyrate (BHB) and acetoacetate (AcAc), produced during fatty acid oxidation when carbohydrate availability is low, can cross the blood-brain barrier via monocarboxylate transporters and serve as an efficient alternative fuel for neurons and astrocytes. Critically, although the brain’s capacity to metabolize glucose declines in many neurological diseases, its ability to utilize ketone bodies appears to remain largely intact.

The evidence base for neuroprotective ketosis is strongest and most mature in the treatment of refractory epilepsy, where the classical ketogenic diet has been used for over a century. More recently, clinical trials have begun to evaluate ketogenic interventions in mild cognitive impairment (MCI) and early Alzheimer’s disease, with encouraging preliminary results. In Parkinson’s disease, multiple sclerosis, autism spectrum disorder, traumatic brain injury, and glioblastoma, the data remain more limited and heterogeneous, though mechanistic work and small clinical studies continue to suggest plausible benefit. This article examines the core neuroprotective mechanisms of ketosis, reviews the clinical evidence by condition, and addresses what “neuroprotective ketosis” likely requires from a practical standpoint.

Core Neuroprotective Mechanisms of Ketone Bodies

Alternative Fuel and Mitochondrial Support

The most straightforward neuroprotective mechanism of ketone bodies is bioenergetic rescue. When neurons can no longer efficiently extract energy from glucose—whether due to insulin resistance, transporter dysfunction, or mitochondrial complex I impairment—BHB and AcAc provide an alternative entry point into the tricarboxylic acid (TCA) cycle via acetyl-CoA. In doing so, they bypass certain bottlenecks in glycolysis and can maintain mitochondrial membrane potential, electron transport chain activity, and ATP production. Preclinical studies have demonstrated that BHB restores mitochondrial respiration by acting on complex II (succinate-ubiquinone oxidoreductase) and that ketogenic feeding promotes enhanced complex II and IV activity in models of neurodegeneration and glaucoma. Beyond simple fuel provision, ketone metabolism appears to stimulate mitochondrial biogenesis, expand the mitochondrial pool, and improve the overall respiratory capacity of neuronal cells.

Epigenetic Signaling: HDAC Inhibition and Beyond

One of the most consequential discoveries in recent ketone body biology came from the Bhatt laboratory at the Gladstone Institutes, published in Science in 2013: D-β-hydroxybutyrate is an endogenous and specific inhibitor of class I histone deacetylases (HDACs), particularly HDAC1, HDAC2, and HDAC3. At millimolar concentrations achieved during physiologic fasting or sustained ketosis, BHB increases global histone acetylation in mouse tissues, upregulating genes encoding oxidative stress resistance factors FOXO3A and metallothionein 2 (MT2). Through HDAC2 and HDAC3 inhibition, BHB has also been found to increase brain-derived neurotrophic factor (BDNF) levels and TrkB signaling in the hippocampus, which may have direct relevance to depression, anxiety, and cognitive resilience. In Alzheimer’s disease models, BHB has been shown to ameliorate amyloid-β-induced downregulation of TrkA expression by specifically inhibiting HDAC1 and HDAC3 in neuronal cell lines, and peripheral BHB administration in APP/PS1 transgenic mice reduces amyloid burden and improves learning and memory.

It is important to note, however, that the HDAC-inhibitory potency of BHB is a matter of ongoing scientific discussion. A 2019 study by Chriett and colleagues in Scientific Reports directly compared BHB to its structural relative butyrate (a gut-derived short-chain fatty acid) and was unable to confirm HDAC inhibition by BHB in vivo or in vitro at comparable concentrations where butyrate showed robust activity. The authors cautioned that BHB may not act pleiotropically as an anti-inflammatory molecule, HDAC inhibitor, and oxidative stress protectant in all cellular contexts. This does not invalidate the extensive body of work demonstrating HDAC-inhibitory effects of BHB at higher concentrations, but it does underscore that the magnitude and tissue specificity of this effect likely depend on the degree and duration of BHB elevation, the cellular milieu, and concurrent metabolic signaling.

Nrf2 Activation and Antioxidant Defense

BHB engages the nuclear factor erythroid 2–related factor 2 (Nrf2) antioxidant pathway through multiple routes. Work in rodent models has demonstrated that ketogenic feeding causes transient elevations in hydrogen peroxide (H₂O₂) and the lipid peroxidation product 4-hydroxynonenal (4-HNE), which act as redox signals to activate Nrf2 via Keap1 redox sensing. Elevated Nrf2 has been detected in brain and liver tissue within the first week of ketogenic diet initiation, leading to induction of downstream antioxidant enzymes including superoxide dismutase (SOD), catalase, and heme oxygenase-1 (HO-1). In spinal cord injury models, ketogenic diet feeding reduced oxidative stress markers and reactive oxygen species products, downregulated NADPH oxidase (NOX2 and NOX4), and upregulated FOXO3a, mitochondrial SOD, and catalase in a dose-dependent manner mediated by class I HDAC inhibition. This convergence of HDAC inhibition and Nrf2 activation represents a particularly powerful axis of neuroprotection, linking epigenetic remodeling to cellular stress resistance.

Anti-Inflammatory and Neuroimmune Modulation

BHB exerts anti-inflammatory effects through several complementary mechanisms. It is an endogenous agonist of the hydroxycarboxylic acid receptor 2 (HCA2, also known as GPR109A), a Gⁱ/₀-coupled receptor expressed on microglia and macrophages. Activation of HCA2 suppresses NF-κB signaling and reduces production of pro-inflammatory cytokines including IL-1β, TNF-α, and IL-6. In ischemic stroke models, BHB-treated mice demonstrated lower expression of markers of astrocyte activation and inflammation (GFAP, IL-1β, TNF), and the investigators hypothesized that long-term BHB administration promotes Nrf2/ARE pathway activation leading to mitochondria-targeted antioxidant gene expression and signaling pathways necessary for neuronal recovery. BHB also inhibits the NLRP3 inflammasome, a multiprotein complex increasingly implicated in neuroinflammatory cascades across Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and traumatic brain injury.

Neurotransmitter Balance: GABA, Glutamate, and Adenosine

The anticonvulsant effects of ketosis have long been attributed in part to shifts in excitatory-to-inhibitory neurotransmitter balance. Ketone body metabolism increases the availability of glutamine for conversion to γ-aminobutyric acid (GABA), enhancing inhibitory tone. Simultaneously, ketosis appears to reduce glutamatergic excitotoxicity, a process implicated not only in epilepsy but also in Alzheimer’s disease, amyotrophic lateral sclerosis, and acute neuronal injury. Adenosine, an endogenous neuromodulator with anticonvulsant and neuroprotective properties, is upregulated during ketosis, and work by Masino and colleagues has demonstrated that the ketogenic diet suppresses seizures in mice in part through adenosine A₁ receptor signaling. The kynurenine pathway—a tryptophan degradation route that produces both neurotoxic (quinolinic acid) and neuroprotective (kynurenic acid) metabolites—is also modulated by ketogenic states, though the clinical significance of this modulation remains an area of active investigation.

Clinical Evidence by Condition

Refractory Epilepsy: The Foundation

The classical ketogenic diet has been used in the management of drug-resistant epilepsy since the 1920s and remains one of the best-established non-pharmacologic interventions in neurology. Multiple randomized controlled trials and systematic reviews have confirmed that approximately fifty percent of children with refractory epilepsy achieve a fifty percent or greater reduction in seizure frequency on a well-formulated ketogenic diet, and a meaningful subset achieve seizure freedom. The diet is considered disease-modifying in certain pediatric epilepsy syndromes, including Dravet syndrome, tuberous sclerosis complex, and GLUT1 deficiency syndrome, where it addresses the underlying metabolic defect directly. Modified versions—the modified Atkins diet, the low glycemic index treatment, and medium-chain triglyceride (MCT) diets—have broadened accessibility while maintaining clinically significant ketosis. Importantly, in epilepsy patients on the ketogenic diet, blood BHB levels correlate most strongly with the degree of seizure control, reinforcing the centrality of sustained ketone elevation to therapeutic benefit.

Mild Cognitive Impairment and Alzheimer’s Disease

Cerebral glucose hypometabolism is one of the earliest detectable abnormalities in Alzheimer’s disease, and the rationale for ketogenic interventions in this population is compelling: provide the brain an alternative fuel it can still utilize. A 2024 systematic review and meta-analysis encompassing ten randomized controlled trials and 691 patients with Alzheimer’s disease found that the ketogenic diet improved mental state and cognitive function, as measured by the Mini-Mental State Examination (MMSE), the Alzheimer’s Disease Assessment Scale–Cognitive subscale (ADAS-Cog), and activities of daily living scales, though the interventions were also associated with elevation in blood lipid levels. A separate critical appraisal using American Academy of Neurology classification of evidence criteria concluded that the strongest evidence to date exists for cognitive improvement in individuals with MCI and in individuals with mild-to-moderate Alzheimer’s disease who are negative for the apolipoprotein ε4 (APOEε4) allele.

Among the more notable individual trials, the KDRAFT study at the University of Kansas demonstrated that ten participants with mild Alzheimer’s disease who followed a ketogenic diet for three months showed significant improvement in cognitive scores, which returned to baseline after a one-month washout period. A 2024 randomized feasibility trial at Johns Hopkins using the modified Atkins diet in older adults with MCI due to early Alzheimer’s disease explored both cognitive and metabolomic outcomes, providing further support for the biological plausibility of the intervention. A 2025 study published in Communications Medicine demonstrated that a modified Mediterranean ketogenic diet (MMKD) produced substantial changes in the plasma lipidome, including global elevation across plasmanyl and plasmenyl ether lipid species, with many changes inversely linked to clinical and biochemical markers of Alzheimer’s disease. These lipidomic findings are particularly intriguing given the role of ether lipids in membrane integrity and myelin structure.

The APOEε4 question deserves emphasis. Several trials have observed that APOEε4-negative individuals appear to derive greater cognitive benefit from ketogenic interventions, raising the possibility that APOEε4 carriers—who already have altered lipid metabolism and may handle dietary fat differently—may require modified protocols. Larger-scale pivotal trials are warranted in both groups, and the field has called for more potent formulations such as exogenous ketone esters (which achieve higher BHB levels more reliably than MCT supplementation alone) to be studied head-to-head against dietary approaches.

Parkinson’s Disease

In Parkinson’s disease, there is a known defect in mitochondrial respiratory chain complex I activity, and the energetic rationale for ketone supplementation is analogous to that in Alzheimer’s disease. All published ketogenic diet studies in Parkinson’s disease have shown significant improvement in motor function, whether measured by vocal quality, gait, freezing, tremor, or balance, though sample sizes remain small. A controlled pilot trial of nutritional ketosis for MCI in Parkinson’s disease suggested cognitive benefit as well. Preclinical evidence is substantially more extensive: BHB rescues mitochondrial respiration and mitigates features of Parkinson’s disease in MPTP toxicity models, and a 2023 animal study demonstrated that ketogenic diet feeding protected dopaminergic neurons, improved motor performance, and reduced inflammation in brain, plasma, and gut—effects that were reproducible via fecal microbiota transplant from ketogenic diet–fed mice, suggesting that the gut microbiome mediates at least part of the neuroprotective effect. Adherence remains a significant practical barrier in this population, and larger, longer trials are needed before clinical practice can change.

Multiple Sclerosis

Multiple sclerosis is an autoimmune demyelinating disorder in which neuroinflammation, oxidative damage, and mitochondrial dysfunction converge. Clinical trials have reported that ketogenic diet improved quality of life, reduced fatigue, and in at least one study, decreased serum neurofilament light chain (sNfL), a biomarker of axonal injury, after six months on the diet—suggesting a measurable neuroprotective effect. The ketogenic diet may also promote remyelination by enhancing expression of neurotrophic factors and promoting oligodendrocyte differentiation. Preclinical work using the cuprizone-induced demyelination model demonstrated that a ketogenic diet alleviated hippocampal demyelination, and a fasting-mimicking diet promoted regeneration and reduced autoimmunity in an experimental autoimmune encephalomyelitis model. However, as systematic reviews have noted, study quality is heterogeneous, sample sizes are small, and some studies described as “ketogenic” permitted carbohydrate intakes too high to achieve meaningful ketosis. Definitive conclusions require larger, longer, and more methodologically rigorous trials.

Neuro-oncology: Glioblastoma

Glioblastoma multiforme (GBM), the most aggressive primary malignant brain tumor, presents a compelling metabolic target for ketogenic intervention. The theoretical framework rests on the Warburg effect: glioblastoma cells are heavily dependent on glycolysis for energy and may lack the metabolic flexibility to efficiently utilize ketone bodies, unlike healthy neurons and astrocytes. A phase 1 safety and feasibility trial of a 3:1 ketogenic diet plus standard-of-care chemoradiation for newly diagnosed GBM, published in Scientific Reports in 2025, demonstrated that the diet was safe, feasible, and associated with stable or improved quality of life, cognitive function, and symptom control, though the study was not powered to assess efficacy. Building on these findings, the NCI-funded, multicenter, randomized phase 2 DIET2TREAT trial (NCT05708352) is currently enrolling 170 patients with newly diagnosed GBM to compare a ketogenic diet versus standard dietary guidance alongside standard-of-care chemoradiation, with overall survival as the primary endpoint. This trial represents the most rigorous test to date of whether metabolic intervention can meaningfully alter the trajectory of the most lethal primary brain cancer.

Other Conditions: Autism, TBI, and ALS

Smaller bodies of evidence and mechanistic work suggest potential applications of ketogenic interventions in autism spectrum disorder (where the diet has been associated with improvements in social behavior and communication in small studies), traumatic brain injury (where ketone body provision may ameliorate the acute energy crisis and secondary injury cascades), and amyotrophic lateral sclerosis (where mitochondrial support and anti-excitotoxic effects are mechanistically relevant). In all of these areas, the evidence remains early-stage and insufficient to support definitive clinical recommendations, but the shared mechanistic substrate—mitochondrial support, inflammation reduction, and epigenetic modulation—provides a coherent rationale for continued investigation.

What “Neuroprotective Ketosis” Likely Requires

Sustained, Not Transient, Ketone Elevation

The neuroprotective signaling cascades attributed to BHB—HDAC inhibition, Nrf2 activation, NLRP3 inflammasome suppression, and upregulation of BDNF—are generally dose- and time-dependent processes. A single morning of skipping breakfast or a brief intermittent fast is unlikely to achieve the degree of BHB elevation (typically in the range of 0.5 to 3.0 mM, depending on the intervention and clinical context) or the duration of exposure necessary to engage these pathways meaningfully. Sustained ketosis achieved through a well-formulated ketogenic diet, structured intermittent fasting, or exogenous ketone supplementation (particularly ketone esters, which produce more reliable and higher BHB elevations than ketone salts or MCT oil alone) is more likely to reach the signaling thresholds observed in preclinical and clinical studies. In the epilepsy literature, the degree of seizure control correlates with circulating BHB levels, and this dose-response relationship likely extends to other neuroprotective endpoints.

Concurrent Glycemic and Insulinemic Context

The neuroprotective benefits of ketosis are not attributable to ketone bodies alone; they arise in the broader metabolic context of reduced glycemia and low insulin signaling. Low insulin and glucose states engage AMP-activated protein kinase (AMPK), activate sirtuins (particularly SIRT1 and SIRT3), and promote cellular stress resistance pathways including autophagy and mitophagy—the selective clearance of damaged mitochondria. Taking an exogenous ketone supplement while consuming a high-carbohydrate, hyperinsulinemic diet may raise circulating BHB, but it will not reproduce the full spectrum of metabolic signaling associated with nutritional ketosis. The clinical implication is that ketogenic neuroprotection likely requires attention to the overall dietary and metabolic pattern, not merely the addition of a ketone supplement to an otherwise unchanged lifestyle.

Microbiome, Micronutrients, and Lipid Monitoring

Ketogenic diets produce significant shifts in gut microbiome composition, and emerging evidence—particularly the fecal microbiota transplant studies in Parkinson’s disease models—suggests that these shifts are not merely a side effect but may actively mediate neuroprotection. At the same time, poorly designed ketogenic diets can cause micronutrient deficiencies (notably selenium, magnesium, calcium, B vitamins, and fat-soluble vitamins), contribute to kidney stone risk, accelerate bone mineral loss, and cause dyslipidemia. The modified Mediterranean ketogenic diet (MMKD) represents a clinically attractive hybrid: it permits slightly higher carbohydrate intake from vegetables and fruits while emphasizing olive oil, fish, and plant-based fats, potentially preserving the ketogenic signaling benefits while mitigating adverse lipid and micronutrient effects. Lipid panels, renal function, micronutrient levels, and bone density should be monitored in any patient on a prolonged ketogenic intervention, and dietary design should be individualized with attention to these parameters.

Practical Clinical Framing

For the integrative clinician considering ketogenic strategies for neuroprotection, the decision matrix involves several layers: the underlying neurological condition (epilepsy, MCI/Alzheimer’s, Parkinson’s, MS, TBI, or glioblastoma), the strength of the evidence base for that condition, patient-specific metabolic risk factors (lipid profile, renal function, sarcopenia risk, APOE genotype), and practical tolerability and adherence considerations.

An example protocol for a patient with early cognitive impairment might combine a mildly carbohydrate-restricted or modified Mediterranean ketogenic dietary pattern with time-restricted feeding (a 14–16-hour overnight fast) to deepen physiologic ketosis naturally. Periodic use of exogenous ketone esters around high-demand cognitive periods or during flares in neurologic symptoms can provide acute BHB elevation without requiring continuous dietary restriction at its most stringent. Serum BHB levels, fasting glucose, fasting insulin, hemoglobin A1c, lipid panel, basic metabolic panel, magnesium, and 25-hydroxyvitamin D represent a reasonable initial monitoring panel, with reassessment at 6–12-week intervals during the first year. Cognitive testing (MoCA or domain-specific neuropsychological assessment) at baseline and at defined intervals provides the clinical outcome measure most relevant to the intervention’s goals.

It bears repeating that the evidence base is strongest for epilepsy (where ketogenic diets are established therapy) and increasingly supportive for MCI and early Alzheimer’s disease (where multiple RCTs now exist). For Parkinson’s disease, multiple sclerosis, autism, TBI, and glioblastoma, the clinical data remain preliminary, and ketogenic interventions in these populations should be framed as investigational and carefully monitored rather than as established standard of care.

Conclusion

Ketosis is more than a dietary curiosity or a weight-loss tool. The convergence of mitochondrial bioenergetics, epigenetic signaling (HDAC inhibition, Nrf2 activation), anti-inflammatory modulation (HCA2 agonism, NLRP3 suppression), and neurotransmitter rebalancing (GABA enhancement, adenosine upregulation) makes sustained ketosis one of the more biologically coherent neuroprotective strategies available. The clinical evidence is most mature in epilepsy and increasingly promising in cognitive impairment and early Alzheimer’s disease, with encouraging but still preliminary data in Parkinson’s disease, multiple sclerosis, and neuro-oncology. As the field moves toward larger, better-designed trials—including the pivotal DIET2TREAT glioblastoma study and anticipated larger cognitive impairment trials—clinicians and patients alike will have a clearer picture of which populations benefit most, what degree and duration of ketosis is required, and how to optimize ketogenic protocols for long-term safety and efficacy. In the meantime, the mechanistic foundation is strong, the safety profile in well-monitored patients is favorable, and the unmet need in neurodegenerative disease is immense.

References

1. Shimazu T, Hirschey MD, Newman J, et al. Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science. 2013;339(6116):211–214. doi:10.1126/science.1227166

2. Chriett S, Dâbek A, Wojtala M, et al. Prominent action of butyrate over β-hydroxybutyrate as histone deacetylase inhibitor, transcriptional modulator and anti-inflammatory molecule. Sci Rep. 2019;9(1):742. doi:10.1038/s41598-018-36941-9

3. Li X, Zhan Z, Zhang J, Zhou F, An L. β-Hydroxybutyrate ameliorates Aβ-induced downregulation of TrkA expression by inhibiting HDAC1/3 in SH-SY5Y cells. Am J Alzheimers Dis Other Demen. 2020;35:1533317519883496. doi:10.1177/1533317519883496

4. Kong G, Liu J, Li R, et al. The ketone metabolite β-hydroxybutyrate attenuates oxidative stress in spinal cord injury by suppression of class I histone deacetylases. J Neurotrauma. 2017;34(18):2645–2655. doi:10.1089/neu.2017.5192

5. Rong L, Peng Y, Shen Q, et al. Effects of ketogenic diet on cognitive function of patients with Alzheimer’s disease: a systematic review and meta-analysis. J Nutr Health Aging. 2024;28(8):100306. doi:10.1016/j.jnha.2024.100306

6. Kossoff EH, Zupec-Kania BA, Auvin S, et al. Optimal clinical management of children receiving dietary therapies for epilepsy: updated recommendations of the International Ketogenic Diet Study Group. Epilepsia Open. 2018;3(2):175–192. doi:10.1002/epi4.12225

7. Buchholz A, Deme P, Betz JF, Brandt J, Haughey N, Cervenka MC. A randomized feasibility trial of the modified Atkins diet in older adults with mild cognitive impairment due to Alzheimer’s disease. Front Endocrinol. 2024;15:1182519. doi:10.3389/fendo.2024.1182519

8. Neth BJ, Huynh K, et al. Consuming a modified Mediterranean ketogenic diet reverses the peripheral lipid signature of Alzheimer’s disease in humans. Commun Med. 2025;5(1):6. doi:10.1038/s43856-024-00682-w

9. Brenton JN, Phillips MCL. Ketogenic interventions in mild cognitive impairment, Alzheimer’s disease, and Parkinson’s disease: a systematic review and critical appraisal. Front Neurol. 2023;14:1123290. doi:10.3389/fneur.2023.1123290

10. Amaral LJ, Nelson TA, Rudnick JD, et al. A phase 1 safety and feasibility trial of a ketogenic diet plus standard of care for patients with recently diagnosed glioblastoma. Sci Rep. 2025;15(1):22234. doi:10.1038/s41598-025-06675-6

11. Gresham G, Butowski NA, Peters KB, et al. DIET2TREAT: A randomized, multi-center, phase 2 trial of a ketogenic diet vs standard dietary guidance in combination with standard-of-care treatment for patients with newly diagnosed glioblastoma. J Clin Oncol. 2024;42(16_suppl):TPS2103. doi:10.1200/JCO.2024.42.16_suppl.TPS2103

12. Tieu K, Perier C, Caspersen C, et al. D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J Clin Invest. 2003;112(6):892–901. doi:10.1172/JCI200318797

13. Krikorian R, Shidler MD, Summers SS, et al. Nutritional ketosis for mild cognitive impairment in Parkinson’s disease: a controlled pilot trial. Clin Park Relat Disord. 2019;1:41–47. doi:10.1016/j.prdoa.2019.07.006

14. Masino SA, Li T, Theofilas P, et al. A ketogenic diet suppresses seizures in mice through adenosine A(1) receptors. J Clin Invest. 2011;121(7):2679–2683. doi:10.1172/JCI57813

15. Kim DY, Hao J, Liu R, Turner G, Shi FD, Rho JM. Inflammation-mediated memory dysfunction and effects of a ketogenic diet in a murine model of multiple sclerosis. PLoS One. 2012;7(5):e35476. doi:10.1371/journal.pone.0035476

16. Price S, Ruppar TM. Ketogenic therapies in Parkinson’s disease, Alzheimer’s disease, and mild cognitive impairment: an integrative review. Appl Nurs Res. 2023;74:151755. doi:10.1016/j.apnr.2023.151755

17. Maalouf M, Rho JM, Bhatt DP. Neuroprotection by the ketogenic diet: evidence and controversies. Front Nutr. 2021;8:782657. doi:10.3389/fnut.2021.782657

18. Phillips MCL, Murtagh DKJ, Gilbertson LJ, Asztely FJS, Lynch CDP. Randomized crossover trial of a modified ketogenic diet in Alzheimer’s disease. Alzheimers Res Ther. 2021;13(1):51. doi:10.1186/s13195-021-00783-x

19. Evangeliou AE, Seyfried TN, et al. Successful application of dietary ketogenic metabolic therapy in patients with glioblastoma: a clinical study. Front Nutr. 2024;11:1489812. doi:10.3389/fnut.2024.1489812

20. Swerdlow RH, Sullivan DK. Ketogenic diet may offer a new approach to treating Alzheimer’s disease. National Center for Advancing Translational Sciences (NCATS). Available at: https://ncats.nih.gov/news-events/news/ketogenic-diet-alzheimers